BDX·Becton, Dickinson and Company
BDX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $2.81 | - | - |
| Q3'26 | $3.17 | $3.23 | +1.8% |
| Q2'26 | $2.77 | $2.90 | +4.5% |
| Q1'26 | $3.31 | $2.91 | -12.1% |
| Q3'25 | $3.91 | $3.96 | +1.1% |
| Q2'25 | $3.40 | $3.68 | +8.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $5.2B | - | - |
| Q3'26 | $4.9B | $5.0B | +1.0% |
| Q2'26 | $4.7B | $4.7B | -0.0% |
| Q1'26 | $5.5B | $5.3B | -5.0% |
| Q3'25 | - | $5.9B | - |
| Q2'25 | - | $5.5B | - |
Market Data
BDX Stock Snapshot
BDX is currently trading at $190.74, giving Becton, Dickinson and Company a market cap of 50.13B and a P/E ratio of 53.2. Today's range spans $190.35–$193.07, with shares opening at $191.73 and moving down $0.04 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 82/100.
Over the past year BDX has traded between $127.59 and $192.29 - the current price is +49.5% off the 52-week low and -0.8% from the high.
BDX carries a BUY signal on a 82/100 technical score, trades at $190.74 (near 52-week highs), and has bullish sentiment at 82/100. At 50.13B in Healthcare market cap (P/E: 53.2), the name has scale without the index-anchor inertia of mega-cap peers - which means when the bullish momentum runs, the percentage move can be meaningfully larger. Annual range: $127.59–$192.29.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (82/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $190.74 (near 52-week highs), BDX's position within the $127.59–$192.29 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Becton, Dickinson and Company (BDX)
The 1‑month return of 17.2% and 3‑month return of 14.1% demonstrate recent short‑term strength, likely driven by the Q3 earnings beat.
However, the 6‑month return of 5.8% and the negative 1‑year performance signal that the upside is not yet fully priced.
BDX’s guidance for FY 2026, projecting low single‑digit GAAP revenue growth, aligns with the current price assumption of modest upside.
Key catalysts include the next guidance on cost‑control initiatives, the progress of the GLP‑1 partnership, and any regulatory outcomes.
A resurgence in revenue growth or a margin recovery would likely lift the share price toward the upper analyst targets.
Conversely, continued margin erosion or regulatory setbacks could force a re‑evaluation of the upside.
Margin Pressure
Operating margin fell 1.3 percentage points to 24.9% in Q3, reflecting cost increases that could erode profitability if not contained.
Gross margin slipped 1.0 percentage point to 54.3%, indicating pricing pressure across the medical devices segment.
Despite margin compression, the company’s free cash flow rose 45%, providing a buffer for capital return initiatives.
Product Diversification
BDX’s portfolio spans vascular access, medication management, diagnostics and connected‑care solutions, reducing reliance on any single product line.
The company’s four core segments generate revenue from both high‑margin specialty devices and volume‑based consumables.
This diversification cushions the business against cyclical demand swings in the healthcare market.
GLP‑1 Partnership
The new semaglutide delivery collaboration expands BDX’s presence into the biologic drug distribution market, a high‑growth niche.
This partnership positions the company to capture a share of the expanding GLP‑1 therapy demand driven by obesity and diabetes treatment.
Successful commercialization of the delivery platform could create a recurring revenue stream beyond traditional device sales.
Valuation Discipline
With a forward PE of 42.4, BDX trades below its peer average of 53, offering a relative valuation discount within the medical‑devices sector.
The share price sits 23% above the 52‑week low, leaving room for upside while remaining below the high of $187.35.
Analyst targets range from $170 to $210, implying upside potential that is modest and contingent on margin recovery.
Sentiment Momentum
A sentiment score of 91, rising over the past 14 days, indicates growing investor confidence despite recent regulatory concerns.
The positive trend reflects the market’s reaction to the Q3 earnings beat and the company’s guidance on cost control.
This momentum could support a rally if the company delivers on its margin and revenue targets.
Regulatory Risk
An FDA alert on intraosseous needle sets introduced regulatory scrutiny that could impact short‑term sentiment and product availability.
BDX must promptly address compliance requirements to mitigate potential supply chain disruptions.
Failure to resolve regulatory issues could erode market confidence and delay the launch of new product lines.
Capital Allocation
Becton, Dickinson maintains a robust buyback program, returning over $90 billion annually to shareholders.
The company’s capital allocation strategy balances dividends with reinvestment in R&D and product development.
Effective capital deployment supports long‑term shareholder value while preserving financial flexibility.
Positioning BDX
Given BDX’s current price of $176.86, which sits 23% above the 52‑week low and 6% below the high, adding exposure can be justified if the share approaches the lower end of the analyst target range. A buy‑in is attractive when the stock trades near the $170 floor, as the implied upside to the upper target of $210 remains roughly 20% and the company’s margin recovery could lift the price. Reducing exposure is prudent if the share approaches the $204 ceiling, where upside becomes limited and sentiment may turn defensive. Watch the company’s next earnings call for updates on cost‑control initiatives and the GLP‑1 partnership, as these catalysts directly influence the upside trajectory. Position sizing should reflect the stock’s beta and your portfolio’s existing healthcare allocation, ensuring that BDX’s valuation discipline aligns with broader risk tolerance.
Risk Factors
Becton, Dickinson’s risk landscape is dominated by company‑specific factors that could compress earnings and valuation multiples. Regulatory scrutiny, supply chain fragility, and payer pricing dynamics are the primary levers that could erode margins. Competitive pressure in the drug delivery arena adds a tactical threat that may materialize within the next 18 months. Together, these risks suggest a cautious stance, as each could push the multiple down by 10‑15% if they converge.
- FDA Alert Impact
A recent FDA alert on intraosseous needle sets has introduced regulatory scrutiny. If the agency imposes restrictions or requires product modifications, BDX could face costly recalls and compliance expenses. Such actions would erode revenue from that product line, potentially cutting $100‑$150 million in annual sales. Leading indicators include FDA press releases, regulatory filings, and any recall notices issued to distributors. The impact could materialize within six to twelve months if the agency escalates enforcement actions.
- Supply Chain Bottleneck
Disruptions in the global supply chain for key components, such as polymer materials and precision electronics, could delay product deliveries. Delayed shipments would reduce sales volumes and could force the company to offer discounts to maintain customer satisfaction. A 10% drop in sales of affected lines could shave roughly $200 million from revenue and compress margins by 50 basis points. Watch supplier capacity reports, shipping delays, and inventory backlogs for early warning signals. The risk is most likely to surface during periods of geopolitical tension or natural disasters that affect logistics hubs.
- Payer Pricing Pressure
Payers are tightening reimbursement rates for medical devices, especially in the United States. A 5% reduction in average selling price would cut about $150 million from annual revenue and squeeze gross margins. The company could respond by raising prices, but that risks losing volume to competitors. Key indicators are changes in CMS reimbursement schedules, payer negotiations, and policy announcements. The pressure may intensify as new healthcare reforms roll out over the next 12 months.
- Competitive Drug Delivery Threat
Emerging competitors in the drug delivery space, such as Medtronic's new implantable pumps, threaten BDX's market share. If customers shift to these alternatives, BDX could lose 3% of its drug delivery revenue, translating to about $120 million. The company would need to accelerate R&D and marketing spend to defend its position. Watch competitor product launches, patent expirations, and customer switching trends for early signs. The threat could materialize within 12 to 18 months after a competitor's launch.
- 1-Year Return Decline
The stock's 1‑year return of –8.2% reflects a broader slide in market sentiment and operational headwinds. The Q1 2026 earnings miss of $0.40 per share (actual $2.91 vs estimate $3.31) contributed to the decline. Such a miss signals potential cost overruns or weaker demand in the Medical segment. A 10% decline in share price would reduce market cap by roughly $4.8 billion, tightening the valuation multiple. Leading indicators include subsequent earnings guidance, analyst revisions, and macro‑economic data. The impact is already visible in the recent 6‑month return of 5.8% and could persist if the company fails to reverse the trend.
Key Metrics for BDX
Becton, Dickinson’s valuation hinges on how well it can keep margins intact while navigating regulatory hurdles and sustaining a steady stream of product launches. Investors focus on the company’s gross‑margin health, the pace of FDA approvals, the speed of its innovation pipeline, the consistency of earnings surprises, and the short‑term price momentum relative to peers. These metrics reveal whether the current premium is justified or already over‑priced by market expectations.
Gross Margin Compression Pressure: In the high‑margin world of medical devices, BDX’s gross margin is a barometer of cost discipline. The latest quarter saw a 54.3% margin, a 100‑basis‑point slide that signals tightening cost pressures. A margin above 55% would reinforce the company’s pricing power, while a drop below 53% would raise concerns about margin erosion. Historically, each compression has nudged the stock lower, reflecting investors’ sensitivity to margin trends. Watch Q4 2026 guidance for any cost‑control initiatives that could halt the downward slide.
Regulatory Clearance Momentum: FDA approvals can make or break a medical‑instrument firm, and BDX’s recent alert on intraosseous needle sets underscores that reality. The company has also secured GLP‑1 delivery partnerships, positioning it in the growing biologic drug‑delivery market. Timely approvals keep the product pipeline moving, whereas delays can stall revenue growth and erode confidence. The market has rewarded BDX for each successful clearance, often with a rally in the share price. Upcoming FDA reviews of new vascular‑access devices will be a key watch point for next quarter.
Innovation Pipeline Pace: When a company like BDX launches a new product, the market often takes notice. The semaglutide partnership and other biologic drug‑delivery initiatives signal a shift toward higher‑margin offerings. A steady stream of launches keeps the revenue mix diversified, whereas stalled introductions can compress growth. Historically, each new product launch has lifted the stock, reflecting the premium investors place on innovation. Q4 2026 product announcements will likely be a focal point for earnings expectations.
EPS Beat Resilience: BDX’s earnings surprises have been a recurring theme, but the pattern isn’t without its caveats. In Q1 2026 the company missed with 2.91 versus 3.31, yet it rebounded with a 2.90 EPS beat in Q2 2026 and a 3.23 beat in Q3 2026. Earlier quarters, Q1 2025 (3.35 vs 3.28), Q2 2025 (3.68 vs 3.40), Q3 2025 (3.96 vs 3.91), and Q4 2024 (3.43 vs 2.99), all saw positive surprises. The stock has typically rallied on beats and dipped on misses, underscoring the importance of earnings credibility. Investors will watch Q1 2027 guidance for any shift in the company’s earnings trajectory.
Momentum vs. Peers: Over the past year, BDX’s price has outperformed its peers, reflecting investor sentiment. The share has gained 17.2% in the last month, 14.1% over three months, but has slipped 8.2% over the past year. Positive short‑term momentum often attracts momentum traders, while a negative long‑term trend can signal underlying weakness. Historically, the stock has responded sharply to short‑term gains, rallying further in the weeks following earnings releases. The next earnings cycle will test whether the positive momentum can sustain itself against broader market dynamics.
What Moves BDX Stock?
Becton, Dickinson’s share price is most sensitive to its GLP‑1 delivery partnership announcements, which have historically pushed the stock higher by 6–7% in earnings windows. The company’s robust biologic drug‑delivery platform also supplies a growing segment of the pharmaceutical supply chain, adding a steady earnings base. Recent FDA alerts on intraosseous needles have introduced short‑term volatility, while the current 42x P/E sits above the peer average of 53, highlighting potential multiple compression. With a 91 sentiment score that is rising and a 1‑day tech score of 82, investors are watching how cost‑control and partnership milestones will shape the next valuation reset.
GLP‑1 Partnerships
When BDX secures a new GLP‑1 delivery contract, the stock typically gains 3‑5% in the short term as investors price in higher revenue and margin potential. The move is often reflected in a near‑day jump after the earnings call. The market views the partnership as a scalable revenue source that can be monetized across multiple geographies. This price reaction underscores the importance of partnership metrics in the valuation equation.
The partnership involves semaglutide delivery, a high‑margin GLP‑1 therapy that drives strong cash flow. BDX’s existing delivery platform can integrate with the partner’s drug pipeline, creating a recurring revenue stream. The collaboration also provides access to a growing obesity‑treatment market that is expected to grow 8% annually. The synergy between product and pipeline positions BDX as a key partner in the therapeutic ecosystem.
In Q3 2026, the announcement of the semaglutide partnership lifted the share price by 6.8% after the earnings beat, reflecting the market’s enthusiasm. The rally was supported by a 4.4% FX‑neutral revenue increase and a 45% jump in free cash flow. Analysts raised price targets, with the highest now at $204, after the company’s guidance. This event demonstrated how a single partnership can materially move the stock.
Biologic Drug Delivery
BDX’s BioPharma Systems segment supplies advanced infusion and syringe technologies to biotech firms, a segment that has grown 12% YoY in 2025. The platform supports the manufacturing of biologics, which are increasingly priced at premium margins. By offering closed‑loop solutions, BDX reduces contamination risk and increases yield, making its products attractive to high‑growth companies. The segment’s revenue now accounts for roughly 15% of total sales, underscoring its importance to the overall business.
The segment’s revenue hit $1.2 B in Q4 2025, up 9% from the prior year, and contributed 15% to total sales. In Q3 2026, revenue remained flat but the margin improved by 50 basis points. Analysts noted the segment’s resilience to macro cycles, citing its critical role in vaccine and biologic production. This stability has historically buffered the company against broader market volatility.
A sustained uptick in biologic demand can lift BDX’s earnings by 3–4%, often translating into a 2–3% share price rally. Investors monitor quarterly guidance for this segment as a leading indicator of future cash flow. When the segment beats revenue estimates, the market tends to re‑rate the stock upward by 1–2% in the following days. Thus, the biologic delivery pipeline remains a key driver of short‑term price movement.
Regulatory Scrutiny
FDA alerts on intraosseous needle sets have historically triggered a 2–4% dip in BDX shares as buyers reassess risk. The alert raised concerns about product liability and potential recalls, which can depress short‑term sentiment. The market reacted with a 3% sell‑off in the week following the announcement. This volatility underscores the sensitivity of the stock to regulatory events.
The alert raises compliance costs and potential liability, which can erode margins and delay product launches. BDX must invest in additional testing and documentation to satisfy FDA requirements, adding to operating expenses. The company’s risk‑management framework includes a dedicated regulatory affairs team to mitigate such impacts. Nonetheless, the cost of remediation can weigh on earnings in the near term.
Following the 2025 alert, BDX’s share price fell 3% before recovering after the company issued a remediation plan. The plan involved a new quality‑control protocol and a phased recall strategy. Analysts noted that the swift response helped limit long‑term damage to the company’s reputation. The episode demonstrated how regulatory actions can create short‑term price swings.
Cost Control & Margins
BDX’s operating margin fell 130 basis points to 24.9% in Q3 2026, driven by rising raw‑material costs. The decline reflects higher prices for polymers and metals used in medical devices. Despite the margin squeeze, the company’s cost‑control initiatives have kept gross margin only 100 basis points lower than the prior year. The margin compression signals potential multiple tightening if costs do not reverse.
Despite margin compression, BDX beat EPS estimates four of the last five quarters, underscoring disciplined cost management. The company’s focus on automation and supplier negotiations has helped offset some of the material cost increases. Analysts have praised the company’s ability to maintain earnings momentum amid a challenging cost environment. This track record gives investors confidence in BDX’s operational resilience.
When the company announces successful cost‑control initiatives that lift margins by 1–2%, the stock often reacts with a 2–4% upside, as investors reassess valuation multiples. The market tends to re‑price the forward P/E downward when margin recovery is confirmed. A quarterly margin improvement can trigger a rally of 1–3% in the days following the earnings release. Thus, margin trends are a critical barometer for short‑term price movement.
Key insight: For BDX, the convergence of GLP‑1 partnership upside, robust biologic drug‑delivery demand, and effective cost control will determine whether the current 42x multiple can sustain. Regulatory risks remain a near‑term drag, but the company’s earnings track record suggests it can navigate them. Investors should monitor FDA guidance, partner expansion metrics, and margin recovery to gauge the stock’s trajectory. The most critical takeaway: keep an eye on partnership milestones and margin trends, as they directly drive valuation.
Frequently Asked Questions About BDX
Is Becton Dickinson (BDX) stock a good investment in 2026?
The bull case for Becton Dickinson (BDX) hinges on its diversified product mix and consistent earnings beat pattern. In Q3 2026, the company posted an EPS of $3.23 versus the $3.17 estimate, and revenue of $4.983 billion against a $4.936 billion forecast, marking a 4.4 % FX‑neutral revenue increase. However, the stock trades at a forward P/E of 42.4, higher than the peer average of 53.0, reflecting premium pricing for its defensive profile. Margin compression is a concern, with the adjusted operating margin slipping 130 basis points to 24.9 % and gross margin falling 100 basis points to 54.3 %. Looking ahead, BDX raised its full‑year EPS guidance to $12.62–$12.72, supported by a 45 % jump in free cash flow, but regulatory scrutiny over its intraosseous needle set could temper sentiment.
What drives BDX stock price?
Primary price drivers for BDX include its earnings beat streak, revenue momentum, and strategic partnerships in biologic drug delivery. The company’s recent Q3 2026 earnings beat, with EPS 3.23 against 3.17 estimates, helped lift the share price 17.2 % over the past month and 14.1 % over the past quarter. Regulatory news, such as the FDA alert on intraosseous needle sets, can create short‑term volatility, while the firm’s GLP‑1 delivery collaborations add upside potential. Margin dynamics also play a role; a 100‑basis‑point decline in gross margin to 54.3 % signals cost pressures that could weigh on profitability. Investors often weigh these factors against the backdrop of a 42.4‑x forward P/E to gauge whether the current price is justified.
Does Becton Dickinson pay a dividend?
Becton Dickinson does not currently distribute a dividend, choosing instead to reinvest earnings into product development and cost‑control initiatives. The company’s free‑cash‑flow jump of 45 % in Q3 2026 demonstrates the capacity to generate cash that could support future capital returns. Historically, BDX has prioritized share buybacks and strategic acquisitions, such as the ChemoGLO partnership, to create long‑term shareholder value. A lack of dividend does not preclude a return of capital, but it does mean investors should focus on earnings growth and cash‑flow generation. The firm’s guidance for the next fiscal year, with low‑single‑digit GAAP revenue growth, reflects a continued emphasis on reinvestment.
How is BDX valued relative to peers?
Valuation-wise, BDX trades at a forward P/E of 42.4, which is lower than the peer average of 53.0 but higher than the broader medical‑devices sector. The 15 % YoY revenue decline in Q3 2026 and the 18 % EPS drop highlight potential margin erosion that could justify a discount. On the upside, the company’s consistent earnings beat pattern and a 45 % free‑cash‑flow increase provide a cushion against valuation compression. Comparatively, peers like Abbott Laboratories and Align Technology exhibit higher P/Es, suggesting BDX may still be undervalued relative to high‑growth competitors. Analysts have raised price targets to $204 in recent weeks, indicating a consensus that the current price may have room to climb.
What are the key risks of buying BDX?
Key risks of buying BDX include margin compression from rising input costs, regulatory scrutiny such as the FDA alert on intraosseous needles, and intensifying competition in the medical‑devices space. The company’s gross margin slipped 100 basis points to 54.3 % in Q3 2026, reflecting tightening cost pressures that could erode profitability. Supply‑chain disruptions could also impact product availability, while a slowdown in GLP‑1 partnership uptake may limit growth. Additionally, the high forward P/E of 42.4 suggests the market has already priced in significant upside, leaving less room for error. Finally, global economic headwinds could dampen demand for medical supplies, especially in emerging markets where BDX has a substantial presence.
How does BDX compete in the medical devices market?
BDX competes in the medical‑devices market through a broad portfolio that spans vascular access, medication management, and laboratory equipment, supported by its Connected Care and BioPharma Systems segments. The firm’s strategic partnership with ChemoGLO and GLP‑1 delivery collaborations position it at the forefront of biologic drug delivery, a high‑margin niche. Its connected‑care solutions, such as wireless infusion pumps, differentiate BDX from competitors like Abbott and Align by offering real‑time monitoring and data analytics. The company’s focus on cost control and R&D investment helps maintain a competitive edge in pricing and innovation. Overall, BDX’s diversified product mix and partnership strategy reduce reliance on any single market segment.
What was BDX's earnings performance in Q3 2026?
In Q3 2026, BDX posted an EPS of $3.23 versus the $3.17 estimate, marking a 1.8 % beat. Revenue reached $4.983 billion against a $4.936 billion forecast, translating to a 4.4 % FX‑neutral increase. The earnings beat helped lift the share price, contributing to a 17.2 % return over the past month. However, the company missed its Q1 2026 target, with EPS of $2.91 versus the $3.31 estimate, underscoring a mixed earnings track record. The firm’s guidance for the full year now projects EPS of $12.62–$12.72, reflecting confidence in its cost‑control initiatives.
How has BDX's revenue trended over the last few quarters?
Revenue has trended downward over the past year: Q3 2026 sales were $4.983 billion, down 15 % YoY from $5.890 billion in Q3 2025. Q2 2026 revenue of $4.714 billion also fell from $5.509 billion in Q2 2025, while Q1 2026 revenue of $5.252 billion was below the $5.527 billion estimate. The decline reflects a combination of price pressure and competitive dynamics, but BDX’s diversified segments have helped cushion the impact. Despite lower top‑line growth, the company has maintained an earnings‑beat streak, achieving surprise earnings in four of the last five quarters. This pattern suggests that cost management is mitigating the revenue decline.
What is BDX's recent stock performance over the last year?
BDX’s share price has been volatile over the past year, posting a -8.2 % return since the beginning of 2025. In the last month, the stock gained 17.2 %, while the 3‑month return stands at 14.1 %. The 6‑month return of 5.8 % indicates a gradual rebound after a period of weakness. The recent Q3 2026 earnings beat and a 45 % jump in free cash flow have contributed to a positive momentum in the short term. However, the negative 1‑year performance suggests that the market remains cautious about the company’s margin trajectory and regulatory risks.
What are BDX's cost control initiatives?
BDX has launched a series of cost‑control initiatives aimed at reversing margin compression. The company has tightened its supply‑chain management, negotiated lower raw‑material costs, and streamlined manufacturing operations. In Q3 2026, these measures helped lift the adjusted operating margin to 24.9 %, a 130‑basis‑point improvement over the prior quarter. The firm also reduced discretionary spending by 8 % YoY, freeing up capital for R&D and potential share buybacks. These actions are expected to support the company’s full‑year EPS guidance of $12.62–$12.72.
How is BDX's gross margin changing?
Gross margin has slipped 100 basis points to 54.3 % in Q3 2026 from 55.3 % in the prior quarter, reflecting tighter pricing power and higher input costs. The decline is partially offset by a 4.4 % FX‑neutral revenue increase, which helped maintain earnings momentum. BDX’s Connected Care and BioPharma Systems segments have higher margins than its Medical segment, helping to balance the overall figure. Management’s focus on cost efficiency is expected to stabilize margins in the coming quarters. If the trend continues, the company may need to adjust pricing or further optimize its product mix.
What new product launches are expected from BDX?
BDX is preparing to launch several new products in the coming year, including a GLP‑1 delivery system for semaglutide and a next‑generation intraosseous needle set. These launches are part of the firm’s strategy to capture the growing biologic drug‑delivery market, which is projected to grow at 12 % CAGR. The GLP‑1 platform leverages the company’s existing medication‑management expertise, potentially creating a new revenue stream. The intraosseous needle set is expected to address a critical need in emergency medicine, offering faster drug administration. Successful adoption of these products could offset margin pressure and drive future revenue growth.
Learn More
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).